Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388993 · ClinicalTrials.gov registry record · NA
Marrow Cellution™ vs. Traditional BMA Harvest Project
A NA study of Hip Arthropathy and Subchondral Cysts, sponsored by Ohio State University.
- Recruiting
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06388993: Recruiting NA study of Hip Arthropathy and Subchondral Cysts, sponsored by Ohio State University.
NCT06388993 is a NA study of Hip Arthropathy and Subchondral Cysts that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 6 participants, below the 62-participant average among 4 other Hip Arthropathy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06388993, a NA study of Hip Arthropathy and Subchondral Cysts, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Six patients with diagnosed bone loss of the hip who have consented to minimally invasive repair will be approached to participate in the study. Participants will have the liquid portion of bone marrow collected using the Zimmer Biomet Biocue system, which is the standard system used by physicians at The Ohio State University, and the novel Marrow Cellutions system™. Bone marrow liquid will be collected from the surgical hip using the Zimmer Biomet Biocue system, and the Marrow Cellutions system™ will be used to collect bone marrow liquid from the non-surgical hip. Following collection, the bone marrow liquid will be processed using the respective systems to concentrate the cells and molecules found in the bone marrow liquid. As part of the standard of care for this arthroscopic procedure, concentrated bone marrow liquid processed using the Zimmer Biomet Biocue system will be delivered to the surgical site as an adjunct to promote healing. Concentrated bone marrow liquid prepared with the Zimmer Biomet Biocue system is given as part of the standard of care for patients undergoing minimally invasive treatment for bone loss of the hip; therefore, the target population for this study are individuals between the ages of 18-50 years with confirmed bone loss of the hip who have consented to minimally invasive repair. In addition to the concentrated bone marrow liquid prepared using the Zimmer Biomet Biocue system, patients will also have bone marrow liquid collected from the non-surgical hip using the Marrow Cellutions™ system. Only concentrated bone marrow liquid produced with the Zimmer Biomet Biocue system will be given to the patient. All concentrated bone marrow liquid produced with the Marrow Cellutions™ system will be sent to the laboratory for analysis. Additionally, white blood cells will be concentrated into an autologous protein solution (APS) using the Zimmer Biomet Plasmax system from blood collected using a routine blood draw. All protein solution produced w
Primary Outcome
Compare total amount of stem cells collected from each sample
Conditions Studied
Interventions
- DEVICE Bone Marrow Collection
Study Locations (1)
Ohio
- Jameson Crane Sports Medicine Institute - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT06388993 shows while recruiting
NCT06388993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 62-participant average among 4 other Hip Arthropathy trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Hip Arthropathy appearing as the primary indexed condition, and to 1 intervention - of which Bone Marrow Collection is the first listed.
NCT06388993 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06388993 about?
NCT06388993 is a clinical study titled "Marrow Cellution™ vs. Traditional BMA Harvest Project". Six patients with diagnosed bone loss of the hip who have consented to minimally invasive repair will be approached to participate in the study. Participants will have the liquid portion of bone marrow collected using the Zimmer Biomet Biocue system, which is the standard system used by physicians a...
What is the current status of trial NCT06388993?
This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2024-03-25. Estimated completion is 2026-03-31.
What conditions does trial NCT06388993 study?
This clinical trial studies the following conditions: Hip Arthropathy, Subchondral Cysts, Avascular Necrosis of Bone.
What interventions are being tested in trial NCT06388993?
The interventions under investigation include: Bone Marrow Collection (DEVICE).
Who is sponsoring clinical trial NCT06388993?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388993 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hip Arthropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI